{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T12:31:23Z","timestamp":1762432283551,"version":"3.44.0"},"reference-count":20,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2023,1,26]]},"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:p>We report a case of a woman in her 30s who struggled with a life-long history of trichotillomania (TTM; hair-pulling disorder), which was unsuccessfully treated with behavioural therapy and selective serotonin reuptake inhibitors. In addition to TTM, our patient had a history of chronic migraine which brought her to our clinic, and treatment with onabotulinumtoxinA (OBTA) was initiated per the Phase III REsearch Evaluating Migraine Prophylaxis Therapy protocol. After experiencing improvement with migraine symptoms, she began off-label treatment with OBTA for her TTM with 45 units being injected, 5 units per site, in diffuse regions of her scalp, primarily on the affected areas of TTM-induced alopecia. The patient reported marked improvement in her TTM signs and symptoms, which resulted in hair regrowth as early as the first follow-up visit 12 weeks post-treatment initiation. Treatment effects were maintained, and additional hair regrowth was observed at the 1-year post-treatment visit, which equated to four cycles of treatment.<\/jats:p>","DOI":"10.1136\/bcr-2022-254006","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T10:22:48Z","timestamp":1675333368000},"page":"e254006","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Amelioration of trichotillomania with onabotulinumtoxinA for chronic migraine"],"prefix":"10.1136","volume":"16","author":[{"given":"Emily Rubenstein","family":"Engel","sequence":"first","affiliation":[{"name":"Department of Neurology, Scripps Clinic, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy-Ann","family":"Ham","sequence":"additional","affiliation":[{"name":"Department of Medicine, Scripps Green Hospital, La Jolla, California, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"2025082801482831000_16.2.e254006.1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Diagnostic and statistical manual of mental disorders. Arlington, VA: American Psychiatric Association, 2013: 251.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"2025082801482831000_16.2.e254006.2","doi-asserted-by":"crossref","DOI":"10.1111\/dth.13818","article-title":"Recent advances in the treatment of trichotillomania (hair-pulling disorder)","volume":"33","author":"Everett","year":"2020","journal-title":"Dermatol Ther"},{"key":"2025082801482831000_16.2.e254006.3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.113.5.e494"},{"key":"2025082801482831000_16.2.e254006.4","doi-asserted-by":"publisher","DOI":"10.1097\/00004583-199509000-00019"},{"key":"2025082801482831000_16.2.e254006.5","article-title":"Therapeutic aspects of trichotillomania: a review of current treatment options","volume":"20","author":"Jafferany","year":"2018","journal-title":"Prim Care Companion CNS Disord"},{"key":"2025082801482831000_16.2.e254006.6","article-title":"Pharmacotherapy for trichotillomania","volume":"9","author":"Hoffman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025082801482831000_16.2.e254006.7","doi-asserted-by":"crossref","unstructured":"Rothbart R , Amos T , Siegfried N , et al . Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev 2013:CD007662. doi:10.1002\/14651858.CD007662.pub2","DOI":"10.1002\/14651858.CD007662.pub2"},{"key":"2025082801482831000_16.2.e254006.8","unstructured":"U.S. Food and Drug Administration . Highlights of prescribing information blepharospasm: 1.25 access data FDA. 2010."},{"key":"2025082801482831000_16.2.e254006.9","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.nicl.2019.101792","article-title":"Cause or effect: altered brain and network activity in cervical dystonia is partially normalized by botulinum toxin treatment","volume":"22","author":"Brodoehl","year":"2019","journal-title":"Neuroimage Clin"},{"key":"2025082801482831000_16.2.e254006.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4610.2010.01766.x"},{"key":"2025082801482831000_16.2.e254006.11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/164_2019_271","article-title":"The history of botulinum toxins in medicine: a thousand year journey","volume":"263","author":"Whitcup","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"2025082801482831000_16.2.e254006.12","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-018-0921-8","article-title":"Guideline on the use of onabotulinumtoxina in chronic migraine: a consensus statement from the European headache Federation","volume":"19","author":"Bendtsen","year":"2018","journal-title":"J Headache Pain"},{"key":"2025082801482831000_16.2.e254006.13","doi-asserted-by":"crossref","DOI":"10.1186\/s10194-019-1038-4","article-title":"Current and emerging evidence-based treatment options in chronic migraine: a narrative review","volume":"20","author":"Agostoni","year":"2019","journal-title":"J Headache Pain"},{"key":"2025082801482831000_16.2.e254006.14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000083259","article-title":"Botulinum toxin: mechanisms of action","volume":"53","author":"Dressler","year":"2005","journal-title":"Eur Neurol"},{"key":"2025082801482831000_16.2.e254006.15","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/164_2019_348","article-title":"Botulinum toxin and pain","volume":"263","author":"Lackovi\u0107","year":"2021","journal-title":"Handb Exp Pharmacol"},{"key":"2025082801482831000_16.2.e254006.16","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1002\/ajmg.b.30922","article-title":"A twin concordance study of trichotillomania","volume":"150B","author":"Novak","year":"2009","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"2025082801482831000_16.2.e254006.17","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1991.01810330052008"},{"key":"2025082801482831000_16.2.e254006.18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.bbr.2014.11.029","article-title":"A comparison of brain volume and cortical thickness in excoriation (skin picking) disorder and trichotillomania (hair pulling disorder) in women","volume":"279","author":"Roos","year":"2015","journal-title":"Behav Brain Res"},{"key":"2025082801482831000_16.2.e254006.19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000518191","article-title":"Trichotillomania: what do we know so far?","volume":"8","author":"Melo","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"2025082801482831000_16.2.e254006.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.05.019"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-254006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T08:48:39Z","timestamp":1756370919000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-254006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":20,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,2,2]]},"published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1136\/bcr-2022-254006"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-254006","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}